66P Real-world data of first-line chemo-immunotherapy for patients with extensive stage SCLC: A multicentre experience from Switzerland and the UK

L. Moliner, N.M. Zellweger, S.M. Schmidt, C. Waibel, P.R. Froesch, P. Häuptle,V. Blum, L. Holer, M. Frueh, S. Bhagani, H-L.J. Gray, S. Cox,T. Khalid, D.C. Scott, S.D. Robinson, L. Hennah, C. Handforth,L.A. Mauti,R. Califano, S.I. Rothschild

Immuno-Oncology and Technology（2022）

引用 0|浏览8

暂无评分

摘要

The addition of immunotherapy (either atezolizumab or durvalumab) to platinum-etoposide for patients with extensive stage SCLC (ES-SCLC) has been recently established as standard first-line treatment based on IMPOWER133 and CASPIAN trials. Yet, the efficacy and safety in a real-world setting remains unclear.

查看译文

关键词

extensive stage sclc,real-world,first-line,chemo-immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要